CompletedPhase 2NCT00086463
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
Studying Drug- or toxin-induced pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Actelion
- Principal Investigator
- Henry Hsu, M.D., MDCoTherix
- Intervention
- Iloprost or placebo(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 12-75 years · All sexes
- Timeline
- 2004 – 2006
Study locations (17)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- UCSD Medical Center, La Jolla, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- UCSF Medical Center, San Francisco, California, United States
- Harbor-UCLA Medical Center, Torrance, California, United States
- The Children's Hospital, Denver, Colorado, United States
- University of Colorado HSC, Denver, Colorado, United States
- Rush Heart Institute, Center for Pulmonary Heart Disease, Chicago, Illinois, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Columbia University Medical Center, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00086463 on ClinicalTrials.govOther trials for Drug- or toxin-induced pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Inhibikase Therapeutics
- RECRUITINGNANCT07529821Additional Effects of Pilates Breathing and Diaphragmatic Breathing Combined With Moderate Intensity Continuous Treadmill Training on Blood Pressure, Chest Expansion, Pulmonary Function and Quality Of Life in Pre-hypertensive PatientsFoundation University Islamabad
- ACTIVE NOT RECRUITINGNCT07312227A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in BoliviaMassachusetts General Hospital
- ENROLLING BY INVITATIONNANCT07558460Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialIstanbul University - Cerrahpasa
- RECRUITINGPHASE2NCT07318597Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)Regeneron Pharmaceuticals
- RECRUITINGNANCT07366879Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial HypertensionGolden Jubilee National Hospital
- RECRUITINGPHASE3NCT07245680COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT06872112A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial HypertensionJoseph C. Wu
See all trials for Drug- or toxin-induced pulmonary arterial hypertension →